Downregulation of FBP1 is reported to contribute to tumor progression and poor survival of hepatocellular carcinoma36 and renal cell carcinoma patients37 and has been touted as a target for therapeutic interventions for these diseases. This evidence concerns the gene FBP1 and renal cell carcinoma.